Libmeldy (Atidarsagene Autotemcel)

Atidarsagene autotemcel consists of the patient’s own CD34+ stem cells that have been transduced ex vivo with a lentiviral vector carrying a functional copy of the ARSA gene. After intravenous infusion, these cells engraft in the bone marrow and continuously express arylsulfatase A, reducing the accumulation of sulfatides that cause neurological damage in metachromatic leukodystrophy.

The dose of Libmeldy is individualized; the prescribing physician determines the cell dose based on the patient’s weight, stem‑cell collection yield, and specific protocol requirements. No fixed dosing schedule is publicly disclosed, and administration is performed as a single intravenous infusion under specialist supervision.

Safety data for Libmeldy in pregnant or lactating women are limited. Current recommendations advise avoiding treatment in these populations unless the potential therapeutic benefit justifies the potential risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with patients and consider alternative options when possible.

To request Libmeldy, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and any necessary import documentation.

Unlike enzyme‑replacement or substrate‑reduction therapies, Libmeldy delivers a one‑time autologous gene‑therapy that aims to restore endogenous arylsulfatase A production. This approach can provide sustained enzyme activity without repeated dosing, but it requires stem‑cell collection, ex vivo manipulation, and careful patient selection, distinguishing it from conventional pharmacologic options.

Libmeldy must be stored refrigerated at 2‑8 °C. The product should be kept in its original container, protected from light, and must not be frozen or shaken. Handling should follow Good Distribution Practice (GDP) guidelines to maintain cell viability until the time of infusion.

After stem‑cell collection and ex vivo transduction, the modified CD34+ cell suspension is infused intravenously over a short period, typically under sterile conditions in a specialized transplant or infusion centre. The procedure is performed by trained healthcare professionals, and patients are monitored closely for immediate infusion reactions.

The most serious risks include insertional mutagenesis leading to potential malignancy, graft failure or poor engraftment resulting in insufficient enzyme production, severe infections during the immunosuppressive conditioning phase, and autoimmune reactions against the introduced enzyme or vector components. Ongoing monitoring is essential to detect these events early.

Libmeldy is contraindicated in patients with active uncontrolled infections, those who are pregnant or breastfeeding unless benefits outweigh risks, individuals with a history of severe allergic reactions to any component of the product, and patients who do not meet the approved diagnostic and disease‑stage criteria for metachromatic leukodystrophy. Clinical judgment determines eligibility.